Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: A nationwide cohort study

  1. Perrottet, Nancy
  2. Fernández-Ruiz, Mario
  3. Binet, Isabelle
  4. Dickenmann, Michael
  5. Dahdal, Suzan
  6. Hadaya, Karine
  7. Müller, Thomas
  8. Schaub, Stefan
  9. Koller, Michael
  10. Rotman, Samuel
  11. Moll, Solange
  12. Hopfer, Helmut ORCID logo
  13. Venetz, Jean-Pierre
  14. Aubert, Vincent ORCID logo
  15. Bühler, Léo
  16. Steiger, Jurg
  17. Manuel, Oriol
  18. Pascual, Manuel
  19. Golshayan, Déla ORCID logo
  20. and the Swiss Transplant Cohort Study (STCS)

Download
journal.pone.0250829.pdf 1,12MB
WeightNameValue
1000 Titel
  • Infectious complications and graft outcome following treatment of acute antibody-mediated rejection after kidney transplantation: A nationwide cohort study
1000 Autor/in
  1. Perrottet, Nancy |
  2. Fernández-Ruiz, Mario |
  3. Binet, Isabelle |
  4. Dickenmann, Michael |
  5. Dahdal, Suzan |
  6. Hadaya, Karine |
  7. Müller, Thomas |
  8. Schaub, Stefan |
  9. Koller, Michael |
  10. Rotman, Samuel |
  11. Moll, Solange |
  12. Hopfer, Helmut |
  13. Venetz, Jean-Pierre |
  14. Aubert, Vincent |
  15. Bühler, Léo |
  16. Steiger, Jurg |
  17. Manuel, Oriol |
  18. Pascual, Manuel |
  19. Golshayan, Déla |
  20. and the Swiss Transplant Cohort Study (STCS) |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-04-30
1000 Erschienen in
1000 Quellenangabe
  • 16(4):e0250829
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0250829 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087104/ |
1000 Ergänzendes Material
  • https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0250829#sec015 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Acute antibody-mediated rejection (AMR) remains a challenge after kidney transplantation (KT). As there is no clear-cut treatment recommendation, accurate information on current therapeutic strategies in real-life practice is needed. KT recipients from the multicenter Swiss Transplant Cohort Study treated for acute AMR during the first post-transplant year were included retrospectively. We aimed at describing the anti-rejection protocols used routinely, as well as patient and graft outcomes, with focus on infectious complications. Overall, 65/1669 (3.9%) KT recipients were treated for 75 episodes of acute AMR. In addition to corticosteroid boluses, most common therapies included plasmapheresis (56.0%), intravenous immunoglobulins (IVIg) (38.7%), rituximab (25.3%), and antithymocyte globulin (22.7%). At least one infectious complication occurred within 6 months from AMR treatment in 63.6% of patients. Plasmapheresis increased the risk of overall (hazard ratio [HR]: 2.89; P-value = 0.002) and opportunistic infection (HR: 5.32; P-value = 0.033). IVIg exerted a protective effect for bacterial infection (HR: 0.29; P-value = 0.053). The recovery of renal function was complete at 3 months after AMR treatment in 67% of episodes. One-year death-censored graft survival was 90.9%. Four patients (6.2%) died during the first year (two due to severe infection). In this nationwide cohort we found significant heterogeneity in therapeutic approaches for acute AMR. Infectious complications were common, particularly among KT recipients receiving plasmapheresis.
1000 Sacherschließung
lokal Transplant rejection
lokal Medical risk factors
lokal Bacterial diseases
lokal Intravenous injections
lokal Antibody therapy
lokal Opportunistic infections
lokal Antiviral therapy
lokal Renal transplantation
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UGVycm90dGV0LCBOYW5jeQ==|https://frl.publisso.de/adhoc/uri/RmVybsOhbmRlei1SdWl6LCBNYXJpbw==|https://frl.publisso.de/adhoc/uri/QmluZXQsIElzYWJlbGxl|https://frl.publisso.de/adhoc/uri/RGlja2VubWFubiwgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/RGFoZGFsLCBTdXphbg==|https://frl.publisso.de/adhoc/uri/SGFkYXlhLCBLYXJpbmU=|https://frl.publisso.de/adhoc/uri/TcO8bGxlciwgVGhvbWFz|https://frl.publisso.de/adhoc/uri/U2NoYXViLCBTdGVmYW4=|https://frl.publisso.de/adhoc/uri/S29sbGVyLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/Um90bWFuLCBTYW11ZWw=|https://frl.publisso.de/adhoc/uri/TW9sbCwgU29sYW5nZQ==|https://orcid.org/0000-0003-1755-2170|https://frl.publisso.de/adhoc/uri/VmVuZXR6LCBKZWFuLVBpZXJyZQ==|https://orcid.org/0000-0003-0352-9797|https://frl.publisso.de/adhoc/uri/QsO8aGxlciwgTMOpbw==|https://frl.publisso.de/adhoc/uri/U3RlaWdlciwgSnVyZw==|https://frl.publisso.de/adhoc/uri/TWFudWVsLCBPcmlvbA==|https://frl.publisso.de/adhoc/uri/UGFzY3VhbCwgTWFudWVs|https://orcid.org/0000-0001-5631-6096|https://frl.publisso.de/adhoc/uri/YW5kIHRoZSBTd2lzcyBUcmFuc3BsYW50IENvaG9ydCBTdHVkeSAoU1RDUyk=
1000 (Academic) Editor
1000 Label
1000 Förderer
  1. Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung |
  2. Swiss University Hospitals and Transplant Centers |
  3. Spanish Society of Transplantation |
  4. Ministerio de Ciencia e Innovación |
  5. Fondation Pierre Mercier pour la Science |
  6. Novartis Foundation |
1000 Fördernummer
  1. -
  2. -
  3. CP18/00073
  4. -
  5. -
  6. -
1000 Förderprogramm
  1. -
  2. -
  3. -
  4. -
  5. -
  6. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Swiss University Hospitals and Transplant Centers |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Spanish Society of Transplantation |
    1000 Förderprogramm -
    1000 Fördernummer CP18/00073
  4. 1000 joinedFunding-child
    1000 Förderer Ministerio de Ciencia e Innovación |
    1000 Förderprogramm -
    1000 Fördernummer -
  5. 1000 joinedFunding-child
    1000 Förderer Fondation Pierre Mercier pour la Science |
    1000 Förderprogramm -
    1000 Fördernummer -
  6. 1000 joinedFunding-child
    1000 Förderer Novartis Foundation |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6452962.rdf
1000 Erstellt am 2023-06-30T13:02:48.828+0200
1000 Erstellt von 337
1000 beschreibt frl:6452962
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet 2023-08-01T10:28:36.352+0200
1000 Objekt bearb. Tue Aug 01 10:28:04 CEST 2023
1000 Vgl. frl:6452962
1000 Oai Id
  1. oai:frl.publisso.de:frl:6452962 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source